Please be advised that due to the high volume of submissions, the ANZCTR is currently experiencing delays in processing submissions from those outside of Australia and New Zealand. As the ANZCTR is funded by Australia and New Zealand, we must prioritise submissions from these countries first. International submissions should allow additional time for registration. Apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Detection of Mycobacterium avium ssp paratuberculosis (MAP) forms in patients with Crohn’s disease and controls”- a prospective clinical study
Scientific title
Detection of Mycobacterium avium ssp paratuberculosis (MAP) forms in patients with Crohn’s disease and controls”- a prospective clinical study
Secondary ID [1] 298192 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease 312775 0
Condition category
Condition code
Oral and Gastrointestinal 311277 311277 0 0
Crohn's disease
Infection 311878 311878 0 0
Other infectious diseases

Study type
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Detection of Mycobacterium avium ssp paratuberculosis (MAP) forms in patients with Crohn’s disease and controls. At the screening visit consent will be obtained and a blood sample will be taken to test MAP from the participants. This study will continue for 2 years. If the study subject is a participant with Crohn’s disease the length of his/her participation will be 52 weeks. If the study subject is a participant in the control group, the length of participation will be less than one week.
Intervention code [1] 314425 0
Early Detection / Screening
Comparator / control treatment
Compare Mycobacterium avium ssp paratuberculosis forms in blood in 40 patients with Crohn’s disease (diagnosed or suspected CD) and 40 controls (no inflammatory bowel disease or irritable bowel syndrome,
Control group

Primary outcome [1] 320018 0
Prevalence of MAP in patients with Crohn’s disease compared to controls using blood culture and specific cell-staining techniques..
Timepoint [1] 320018 0
Crohn's patients will be followed up 12-month.
Secondary outcome [1] 370259 0
Detection of MAP blood culture using cell-staining method.
Timepoint [1] 370259 0
Followed up at 3 months and 12 months post blood test.

Key inclusion criteria
• Test group: 40 patients diagnosed with CD or suspected to be diagnosed with CD.
• Controls: 40 patients (no inflammatory bowel disease, no irritable bowel syndrome, no pathology in the terminal ileum) who are referred to the CDD for a routine colonoscopy due to family history of bowel cancer or polyps or similar reason. These participants are ‘normal’ from the point of view of Crohn’s disease which will be excluded on colonoscopy from examination of the terminal ileum. If “a patient in the control group” is diagnosed as having Crohn’s disease in the screening period, the participant will still be included in the test group.
• Provide written informed consent to participate as shown by a signature on the consent form.
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
• Consent not obtained.
• Any contraindications for drug/test – Vaccinated BCG, taking Infliximab or Anti-MAP therapy
• Clinical evidence of any disease which might interfere with the patient’s ability to enter the trial.
• Unable to communicate well with the investigators and to comply with the study requirements.

Study design
Defined population
Statistical methods / analysis
Descriptive statistics will be conducted for CDAI, Harvey-Bradshaw index, QOL and MAP results. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) will be calculated for MAP results based on the generated sample size. Correlations will be conducted between CDAI, Harvey-Bradshaw, QOL, histopathology, stool test and MAP test results. Independent t-test or equivalent tests will be conducted to compare CDAI, Harvey Bradshaw Index, QOL, stool test and MAP results between CD and controls. Paired t-test or equivalent test will be used to assess differences in CDAI, Harvey-Bradshaw Index, QOL, stool test and MAP results between patients with CD at two time points (pre and post Anti-MAP treatment). Statistical significance will be set at 5%.

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 13723 0
Centre for Digestive Diseases - Five Dock
Recruitment postcode(s) [1] 26466 0
2046 - Five Dock

Funding & Sponsors
Funding source category [1] 302733 0
Commercial sector/Industry
Name [1] 302733 0
Axent Medical
Address [1] 302733 0
44 East Street, Five Dock, New South Wales, 2046
Country [1] 302733 0
Primary sponsor type
Centre for Digestive Diseases
Level 1, 229 Great North Road, Five Dock, New South Wales, 2046.
Secondary sponsor category [1] 302666 0
Name [1] 302666 0
Address [1] 302666 0
Country [1] 302666 0

Ethics approval
Ethics application status
Ethics committee name [1] 303338 0
Centre for Digestive Disease Ethics Committee
Ethics committee address [1] 303338 0
Level 1
229, Great North Road, Five Dock, NSW. 2046
Ethics committee country [1] 303338 0
Date submitted for ethics approval [1] 303338 0
Approval date [1] 303338 0
Ethics approval number [1] 303338 0

Brief summary
This study is a single-centre, single-blind, prospective clinical trial evaluating the effect of a new diagnostic test for discrimination of CD and controls. We hypothesised that Mycobacterium avium subspecies paratuberculosis (MAP) is the leading infectious cause for CD. Therefore, developing a simple diagnostic test for MAP detection is worthy of investigation for diagnosis of CD and determining success of anti-mycobacterial therapy in patients with CD. The results of the study will provide evidence for the association between MAP and CD as well as establishing an affordable, less invasive, accurate and efficient diagnostic test for CD and/or monitoring.’
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 93326 0
Prof Thomas Julius Borody
Address 93326 0
Centre for Digestive Diseases,
Level 1, 229 Great North Road, Five Dock, NSW, 2046.
Country 93326 0
Phone 93326 0
Fax 93326 0
Email 93326 0
Contact person for public queries
Name 93327 0
Dr Annabel Clancy
Address 93327 0
Centre for Digestive Diseases,
Level 1, 229 Great North Road, Five Dock, NSW, 2046.
Country 93327 0
Phone 93327 0
Fax 93327 0
Email 93327 0
Contact person for scientific queries
Name 93328 0
Dr Annabel Clancy
Address 93328 0
Centre for Digestive Diseases,
Level 1, 229 Great North Road, Five Dock, NSW, 2046.
Country 93328 0
Phone 93328 0
Fax 93328 0
Email 93328 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
What supporting documents are/will be available?
No other documents available
Summary results
No Results